Navigation Links
Medicare modernization act did not change chemotherapy as feared
Date:10/7/2007

DURHAM, N.C. -- Cancer patients receiving chemotherapy have not noticed a restriction in their access to treatment following the enactment of the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (MMA), despite the act's significant reduction in government reimbursement to oncologists, according to a new study led by researchers in the Duke Clinical Research Institute (DCRI).

Critics of the MMA often said that it would reduce patients access to chemotherapy services, because doctors would receive 30 to 40 percent less reimbursement from the government for administering treatment, said Kevin Schulman, M.D., director of the DCRIs Center for Clinical and Genetic Economics, and senior investigator on the study. Our study showed that patients actually do not perceive barriers to their access to chemotherapy and perceptions about access are really the same among patients who received treatment before the legislation went into effect, and those who received it afterwards.

The team's findings will be published in the November 15, 2007 print edition of the journal Cancer, but also will appear earlier in the journals October 8, 2007 online edition. The study was funded by a grant from the National Patient Advocate Foundations Global Access Project, which brings together 42 national healthcare stakeholder groups -- such as pharmaceutical companies and advocacy groups -- to fund health research projects. The Project has focused on examining the MMAs consequences for patients, providers and healthcare systems.

The Duke researchers examined the results of 1421 surveys completed via the internet by 684 patients who had received chemotherapy prior to the enactment of the MMA and 737 patients who were treated after it went into effect. Respondents answered questions related to issues including the amount of time they waited to start chemotherapy after their initial cancer diagnosis, and how far they had to travel to get their treatments.

When the act was passed in 2003, many doctors and patient advocates were concerned about the consolidation of services it might necessitate, such as the moving of chemotherapy services to hospital rather than outpatient settings and the elimination of staff positions, said Joelle Friedman, a DCRI researcher and lead author on the paper. They were afraid these changes would affect patients access to care, but our study showed that these concerns turned out to be largely unwarranted.

About half of the patients surveyed in each group were under the age of 65 and half were over 65. The majority of patients in each group reported being either satisfied or very satisfied with the care they received from their oncologists, Friedman said.

The researchers also found no difference in the amount of time from diagnosis to initiation of chemotherapy between the two groups; the median lapse in time was 22 days in both groups, Friedman said.

Patients reported an average travel time of 30 minutes to the location of their chemotherapy appointments, both before and after the implementation of the act, she said.

The speculation that treatment location would change -- that patients would either be forced to travel farther for therapy or switch treatment locations in the middle of therapy -- also proved to be unfounded, Friedman said.

The MMA represented the largest overhaul of the Medicare system since it was created in 1965. Changes included a new prescription drug benefit, and a $25 billion allocation of funds to rural hospitals. One key provision, however, was a significant reduction in Medicare reimbursement to healthcare providers. Oncologists were strongly affected, due to a perception that they had been over-compensated in the past.


'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Medicare Drug Deadline not to be extended
2. House heads for Medicare drug vote
3. New Medicare Plan - Mixed Reaction among Pharmacists.
4. Medicare Data would help in Drug Validation
5. Medicare Queries Expected To Increase Over Time
6. Medicare to cover services provided by rural health care personnels.
7. Cancer test expenses taken up by Medicare
8. Nurse Practitioners Are Not Recognized By Medicare
9. Medicare Drug Plan Is Not Working in The US
10. Blue Cross Signs Up 110,000 Minnesotans For Part D Medicare Plans
11. Rising Medicare costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... NV (PRWEB) , ... May 02, 2016 , ... ... Pharmacy Times, has announced a new Specialty Pharmacy Patient Satisfaction Award that will ... based on the quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction ...
(Date:5/2/2016)... ... May 02, 2016 , ... The 2016 World Ultimate & Guts Championship (WUGC) Mixed roster was ... made the cut. The WUGC is being held in London, England this year from June ... the men’s division, another gold in the women’s masters division, and a silver in the ...
(Date:5/2/2016)... ... , ... Pregnancy Awareness Month offers a great time to get familiar with ... are ready to have a baby, it’s best to get started before age becomes ... Personal Conception & Pregnancy Organizer, written for women who plan on becoming pregnant to ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... division of Permobil, recently completed two groundbreaking studies that determined that the adjustability ... – are critical in the prevention of pressure injuries, which are now referred ...
(Date:5/2/2016)... Washington, DC (PRWEB) , ... May 02, 2016 , ... ... “ How CMS’s Medicare Part B Payment Model Could Transform the Pharma Landscape .” ... an eye on reducing its spend on provider-administered drugs while preserving care provided to ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 29, 2016 ReportsnReports.com adds ... market research report that provides an overview of ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:4/29/2016)... 2016 Glycotope GmbH, a clinical-stage ... the appointment of Dr. Alfredo Zurlo as ... oncologist with many years clinical experience and a proven ... last role was at Mologen AG where he was ... Previously Dr. Zurlo held various positions at F Hoffmann ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
Breaking Medicine Technology: